Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 10/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.37 |
| ▸ | KDR | P35968 | 8/20 | 0.37 |
| ▸ | SORD | Q00796 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129624 | 0.94 | CXCR4 (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2125333 | 0.87 | FGFR1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2693461 | 0.87 | TSHR (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2124334 | 0.85 | MEN1 (0.40) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4071647 | 0.83 | ALDH1A1 (0.38) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2125726 | 0.81 | MEN1 (0.37) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4068215 | 0.81 | FGFR1 (0.35) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL4215152 | 0.80 | SORD (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2124123 | 0.80 | MEN1 (0.46) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL2123754 | 0.80 | FGFR1 (0.35) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476290-B2 | Compound having spiro-bonded cyclic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120101280-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2444402-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101280-A1 | COMPOUND HAVING SPIRO-BONDED CYCLIC GROUP AND USE THEREOF | CXCR4, CXCL12, CCR5 | FGFR1 647/4885FGFR2 2573/4885FGFR4 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.